Bristol-Myers Squibb (NYSE:BMY) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

BMY Stoklara Genel Bakış

Bristol-Myers Squibb Company biyofarmasötik ürünleri keşfeder, geliştirir, lisanslar, üretir, pazarlar, dağıtır ve dünya çapında satar.

Şirket hakkında

BMY temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	5/6

Ödüller

Adil değer tahminimizden 61.3% daha düşük bir oranda işlem görüyor

Kazançların yılda 49.05% oranında artması öngörülüyor

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Yüksek borç seviyesine sahip

4.54% temettüsü kazançlar tarafından iyi karşılanmıyor

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Tactical Moves Steer Company Towards Robust Growth And Margin Expansion

US$54.20

3.2% undervalued

-1.57%

Revenue growth p.a.

Updated

Bristol-Myers Squibb Company Rakipler

Zoetis

NYSE:ZTS

US$84.8b

Pfizer

NYSE:PFE

US$165.5b

Merck

NYSE:MRK

US$275.3b

Johnson & Johnson

NYSE:JNJ

US$384.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bristol-Myers Squibb
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$52.48
52 Haftanın En Yüksek Seviyesi	US$57.65
52 Haftanın En Düşük Seviyesi	US$39.35
Beta	0.46
11 Aylık Değişim	7.76%
3 Aylık Değişim	27.63%
1 Yıllık Değişim	-6.93%
33 Yıllık Değişim	-8.03%
5 Yıllık Değişim	1.25%
Halka arzdan bu yana değişim	2,356.10%

Son Haberler & Güncellemeler

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Oct 06

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Sep 27

Recent updates

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Aug 15

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Aug 06

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Jul 27

Bristol Myers Squibb: The More It Drops, The More I Buy

Jul 16

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Jun 13

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Jun 09

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

Jun 03

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

May 23

Bristol-Myers Squibb: A Lost Decade?

May 03

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

Apr 29

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Apr 22

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Apr 12

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Apr 02

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 21

Bristol-Myers Squibb Is Not A Buy For Me

Mar 19

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Mar 07

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Mar 07

We Think Bristol-Myers Squibb's (NYSE:BMY) Healthy Earnings Might Be Conservative

Feb 20

Bristol-Myers Squibb Company (NYSE:BMY) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Feb 06

Bristol-Myers Squibb: Massive Discount Spells Opportunity

Feb 04

Hissedar Getirileri

	BMY	US Pharmaceuticals	US Pazar
7D	-0.8%	0.1%	0.6%
1Y	-6.9%	18.8%	30.3%

Getiri vs. Endüstri: BMY geçen yıl % 23.1 oranında getiri sağlayan US Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: BMY geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	4.8%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

İstikrarlı Hisse Senedi Fiyatı: BMY son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: BMY 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1887	34,100	Chris Boerner	www.bms.com

Bristol-Myers Squibb Company dünya çapında biyofarmasötik ürünler keşfeder, geliştirir, lisanslar, üretir, pazarlar, dağıtır ve satar. Hematoloji, onkoloji, kardiyovasküler, immünoloji, fibrotik ve nörobilim hastalıkları için ürünler sunmaktadır. Şirketin ürünleri arasında valvüler olmayan atriyal fibrilasyonda inme/sistemik emboli riskini azaltmak ve DVT/PE tedavisi için Eliquis; mesane, kan, CRC, baş ve boyun, RCC, HCC, akciğer, melanom, MPM, mide ve özofagus kanseri dahil olmak üzere çeşitli anti-kanser endikasyonları için Opdivo bulunmaktadır; Multipl miyelom için Pomalyst/Imnovid; aktif romatoid artrit ve psoriatik artrit için Orencia; ve Philadelphia kromozomu pozitif kronik miyeloid lösemi tedavisi için Sprycel.

Bristol-Myers Squibb Company Temel Bilgiler Özeti

Bristol-Myers Squibb'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BMY temel i̇stati̇sti̇kler
Piyasa değeri	US$108.34b
Kazançlar(TTM)	-US$6.54b
Gelir(TTM)	US$46.51b

2.3x

P/S Oranı

-16.3x

F/K Oranı

BMY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BMY gelir tablosu (TTM)
Gelir	US$46.51b
Gelir Maliyeti	US$11.08b
Brüt Kâr	US$35.43b
Diğer Giderler	US$41.97b
Kazançlar	-US$6.54b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Oct 31, 2024

Hisse başına kazanç (EPS)	-3.23
Brüt Marj	76.18%
Net Kâr Marjı	-14.06%
Borç/Özkaynak Oranı	306.9%

BMY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

4.6%

Mevcut Temettü Verimi

-74%

Ödeme Oranı

BMY güvenilir bir temettü ödüyor mu?

BMY temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman BMY satın almanız gerekir?
Bristol-Myers Squibb temettü tari̇hleri̇
Eski Temettü Tarihi	Oct 04 2024
Temettü Ödeme Tarihi	Nov 01 2024
Eski temettüye kadar geçen günler	6 days
Temettü ödeme tarihine kadar geçen günler	22 days

BMY güvenilir bir temettü ödüyor mu?

BMY temettü geçmişine ve kıyaslamalara bakın

BMY Stoklara Genel Bakış

Ödüller

Risk Analizi

Tactical Moves Steer Company Towards Robust Growth And Margin Expansion

Bristol-Myers Squibb Company Rakipler

NYSE:ZTS

US$84.8b

NYSE:PFE

US$165.5b

NYSE:MRK

US$275.3b

NYSE:JNJ

US$384.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Recent updates

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting

Upcoming dividend of US$0.60 per share

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma

Second quarter dividend of US$0.60 announced

Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma

European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company's (NYSE:BMY) Share Price Is Matching Sentiment Around Its Revenues

Bristol-Myers Squibb: A Potential Comeback In Healthcare

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Consensus EPS estimates fall by 18%

Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb: The More It Drops, The More I Buy

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

First quarter dividend of US$0.60 announced

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Is Bristol-Myers Squibb (NYSE:BMY) A Risky Investment?

Bristol Myers: Quality Fundamentals Suppressed By Interest Rates

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly Loss

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Bristol-Myers Squibb: A Lost Decade?

Lacklustre Performance Is Driving Bristol-Myers Squibb Company's (NYSE:BMY) Low P/S

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

Consensus EPS estimates fall by 24%

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Upcoming dividend of US$0.60 per share

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb (NYSE:BMY) Is Due To Pay A Dividend Of $0.60

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Is Not A Buy For Me